BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Biotechnology

Healthcare
$1.81 -0.39%

-$0.03 today

Market cap
$144.85M
Beta
0.29
P/E (TTM)
-1.5
EPS (TTM)
-$4.95
52W Low $7.00High $14.87

Volume 0.58M

Average 0.37M

BBOT Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 31.14M shares rose 32.5% year over year, ahead of the +25.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +15.0% a year.

Context

  • Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +32.5% holds above the trailing-twelve-month pace of +25.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
31.14M+0.0% QoQ
Last fiscal yearDec 2025
31.14M+87.2% YoY
LTMMar 2026
27.33M+25.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.5%——
1 year+87.2%——
3-year CAGR+15.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
31.14M USD
Year-over-year change
+87.2%
4-year CAGR
+11.0%

Weighted Avg Shares (Diluted) vs competitors

How BBOT compares with its peers on the latest reported figures

  • BBOT's LTM Mar 2026 weighted avg shares (diluted) of 27.33M shares is the lowest of the 10 companies compared; the peer median is 60.16M shares.
  • Its year-over-year change of +25.4% is the 4th highest of 10, against a peer median of +13.3%.
  • Over three fiscal years its annual growth of +15.0% compares with a peer median of +13.4%.
BBOT Competitors Peer median
Weighted Avg Shares (Diluted) for BBOT and competitors
Company Period LTM YoY 3-year CAGR
TNGXTango Therapeutics, Inc.LTM Sep 2026145.89M +32.5%+9.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026108.1M +31.0%+21.3%
PHATPhathom Pharmaceuticals, Inc.LTM Mar 202675.43M +13.3%+23.1%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
KODKodiak Sciences Inc.LTM Sep 202660.16M +14.0%+0.6%
OCSOculis Holding AGLTM Mar 202654.96M +27.5%+16.9%
URGNUroGen Pharma Ltd.LTM Mar 202648.8M +11.9%+28.3%
SEPNSepterna, Inc.LTM Sep 202645.24M +9.0%—
ANABAnaptysBio, Inc.LTM Mar 202629.47M +0.4%+3.6%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 202627.33M +25.4%+15.0%
Peer median (excluding BBOT) 60.16M+13.3%+13.4%

Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development0056.29M73.11M121.2M
Selling, General & Admin43.36K3.52K8.49M7.76M24.62M
Operating Expenses43.36K3.52K64.77M80.86M145.82M
Depreciation & Amortization74.33K3.52K92K208K610K
EBITDA(43.36K)(3.52K)(64.68M)(80.66M)(145.21M)
EBITDA Margin—————
Operating Income(43.36K)(3.52K)(64.77M)(80.86M)(145.82M)
Operating Margin—————
Interest Income0072K8.46M11.34M
Interest Expense00000
Other Income / Expenses0072K8.18M11.78M
Income Before Tax(43.36K)(3.52K)(64.7M)(74.28M)(134.04M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(43.36K)(3.52K)(64.7M)(74.28M)(134.04M)
Net Margin—————
EPS (Basic)(0.00)0.00(3.16)0.46(4.30)
EPS (Diluted)(0.00)(0.00)(3.16)0.46(4.30)
Weighted Avg Shares20.49M20.49M20.49M16.64M31.14M
Weighted Avg Shares (Diluted)20.49M20.49M20.49M16.64M31.14M

BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Intrinsic Alpha fair value

Locked

Current Price

$1.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.